Observational Comparative Effectiveness of Pharmaceutical Treatments for Obesity within the Veterans Health Administration.

Abstract:

STUDY OBJECTIVE:To compare the effectiveness of weight-management medications used to assist with weight loss in real-world clinical practice in the Veterans Health Administration (VHA). DESIGN:Retrospective, multicenter, observational cohort study. DATA SOURCE:National VA Corporate Data Warehouse. PATIENTS:A total of 66,035 VA patients aged 18 years or older with a body mass index of 25 kg/m2 or greater who had an initial fill for a study medication (orlistat [6153 patients], phentermine [304 patients], lorcaserin [298 patients], or phentermine-topiramate extended release [233 patients]) or participation in the VA's MOVE! weight-management program with at least three total visits in a clinic coded as a MOVE clinic in the subsequent 24 weeks (59,047 patients) between January 1, 2012, and July 1, 2016. MEASUREMENTS AND MAIN RESULTS:The primary outcome was the percentage change in weight from baseline to at least 20 weeks or later (i.e., closest weight to 6 months). Secondary outcomes were difference in the percentage of weight loss at 12 and 36 weeks; changes in blood pressure, hemoglobin A1c , high-density and low-density lipoprotein cholesterol and triglyceride levels; and percentage of patients who achieved at least a 5% and 10% weight loss at 6 months from baseline in each group after at least 20 weeks. For the primary outcome, the percentage decrease in weight from baseline after at least 20 weeks in the lorcaserin, phentermine-topiramate, phentermine, orlistat, and MOVE! groups were 3.6%, 4.1%, 3.6%, 2.1%, and 1.6%, respectively (phentermine-topiramate group vs. MOVE! group, p<0.05). Achievement of at least a 5% weight loss after at least 20 weeks differed significantly among groups, ranging from 26.2% for the MOVE! Program only group to 40.3% for patients in the phentermine-topiramate group. CONCLUSION:In the VA population, the effectiveness of four available weight-management medications was similar. Patients receiving phentermine-topiramate had a greater proportion of weight loss after at least 20 weeks compared with those solely enrolled in the VA's MOVE! weight-management program.

journal_name

Pharmacotherapy

journal_title

Pharmacotherapy

authors

Grabarczyk TR

doi

10.1002/phar.2048

subject

Has Abstract

pub_date

2018-01-01 00:00:00

pages

19-28

issue

1

eissn

0277-0008

issn

1875-9114

journal_volume

38

pub_type

杂志文章,多中心研究
  • Variability in activity of hepatic CYP3A4 in patients infected with HIV.

    abstract:STUDY OBJECTIVES:To evaluate hepatic cytochrome P450 (CYP) 3A4 activity in patients infected with the human immunodeficiency virus (HIV) using the erythromycin breath test (ERMBT), and to examine the relationship of the ERMBT to plasma concentrations of indinavir and nelfinavir. DESIGN:Prospective observational study....

    journal_title:Pharmacotherapy

    pub_type: 临床试验,杂志文章

    doi:10.1592/phco.20.11.898.35262

    authors: Slain D,Pakyz A,Israel DS,Monroe S,Polk RE

    更新日期:2000-08-01 00:00:00

  • Simvastatin-associated memory loss.

    abstract::The statins are widely used to treat dyslipidemias. They are generally associated with mild adverse effects, but rarely, more serious reactions may occur. A 51-year-old man experienced delayed-onset, progressive memory loss while receiving simvastatin for hypercholesterolemia. His therapy was switched to pravastatin, ...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:10.1592/phco.21.7.767.34577

    authors: Orsi A,Sherman O,Woldeselassie Z

    更新日期:2001-06-01 00:00:00

  • Single-Dose Basiliximab Induction in Low-Risk Renal Transplant Recipients.

    abstract:OBJECTIVES:To compare the efficacy of a single dose of basiliximab with two doses in preventing acute rejection in selected low-risk renal transplant recipients. METHODS:This observational study of 760 kidney transplant recipients considered to be at low immunologic risk (peak panel reactive antibody less than 10%) co...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:10.1002/phar.1774

    authors: Cunningham KC,Hager DR,Fischer J,D'Alessandro AM,Leverson GE,Kaufman DB,Djamali A

    更新日期:2016-07-01 00:00:00

  • Resistance to antimicrobial agents: an update.

    abstract::Decades of overuse and misuse of antibiotics have turned the resistance problem into a crisis. Preventive and corrective measures are urgently needed. This article presents a broad overview of the status of antimicrobial resistance. Resistance in key bacterial pathogens such as enterococci, staphylococci, pneumococci,...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1592/phco.24.18.203S.52236

    authors: Rybak MJ

    更新日期:2004-12-01 00:00:00

  • Cerivastatin-induced rhabdomyolysis: 11 case reports.

    abstract::3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are a frequently prescribed class of drugs that are generally well tolerated by most patients. A rare, yet serious side effect associated with these drugs is rhabdomyolysis. Although all HMG-CoA reductase inhibitors can cause this adverse effect, pre...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1592/phco.22.7.533.33674

    authors: Ravnan SL,Locke C,Yee WP,Haase K

    更新日期:2002-04-01 00:00:00

  • Pharmacists' assessment of dispensing errors: risk factors, practice sites, professional functions, and satisfaction.

    abstract::Certain demographic, practice, staffing, and pharmacist satisfaction variables may contribute to dispensing errors. A survey was randomly mailed to 7298 (50%) Texas pharmacists, of which 2862 were returned (39% response rate). Responders were 2437 pharmacists who indicated that they were in practice. Of these, 535 (23...

    journal_title:Pharmacotherapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1592/phco.21.6.614.34544

    authors: Bond CA,Raehl CL

    更新日期:2001-05-01 00:00:00

  • Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.

    abstract::Exenatide is an incretin mimetic indicated for the treatment of type 2 diabetes mellitus in combination with a sulfonylurea, a thiazolidinedione, metformin, or metformin plus a sulfonylurea or thiazolidinedione. Exenatide lowers postprandial blood glucose levels by stimulating glucose-dependent insulin secretion, inhi...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:10.1592/phco.27.10.1449

    authors: Sheffield CA,Kane MP,Busch RS

    更新日期:2007-10-01 00:00:00

  • Complementary and alternative medicine use among individuals participating in research: implications for research and practice.

    abstract:STUDY OBJECTIVES:To determine the frequency and type of complementary and alternative medicine (CAM) use among healthy volunteers participating in research, and to investigate the potential for interactions between commonly used CAM modalities and various drugs. DESIGN:Prospective evaluation. SETTING:University gener...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:10.1592/phco.26.12.1794

    authors: Welder GJ,Wessel TR,Arant CB,Schofield RS,Zineh I

    更新日期:2006-12-01 00:00:00

  • Therapy with macrolides in patients with cystic fibrosis.

    abstract::Cystic fibrosis affects 1/2500 individuals and is the most common lethal autosomal recessive disease in people of northern European descent. It is characterized by chronic infections with mucoid Pseudomonas aeruginosa and progressive deterioration of respiratory function. Much research has focused on the inflammatory ...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1592/phco.22.3.227.33544

    authors: Gaylor AS,Reilly JC

    更新日期:2002-02-01 00:00:00

  • Trends in antimicrobial resistance among today's bacterial pathogens.

    abstract::Resistance of nosocomial and community-acquired pathogens to antimicrobial agents is a serious problem with significant clinical consequences. Microbiologic surveillance data, such as those provided by the National Nosocomial Infections Surveillance System, supply information on current nosocomial pathogens in the Uni...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:

    authors: Thornsberry C

    更新日期:1995-01-01 00:00:00

  • Therapeutic drug monitoring of continuous-infusion acylovir for disseminated herpes simplex virus infection in a neonate receiving concurrent extracorporeal life support and continuous renal replacement therapy.

    abstract::Disseminated herpes simplex virus (HSV) infection in neonates represents a devastating entity that yields high mortality. Acyclovir is the primary antiviral agent used to treat life-threatening HSV infections in neonates; however, even though the agent has reduced morbidity overall from these infections, mortality wit...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:10.1002/phar.1526

    authors: Cies JJ,Moore WS 2nd,Miller K,Small C,Carella D,Conley S,Parker J,Shea P,Chopra A

    更新日期:2015-02-01 00:00:00

  • Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management.

    abstract:STUDY OBJECTIVES:To assess the use and safety of concurrent administration of voriconazole and sirolimus-which is contraindicated-and to determine approaches for appropriately managing patients who receive both drugs. DESIGN:Retrospective medical record review. SETTING:University-affiliated medical center. PATIENTS:...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:10.1592/phco.28.6.719

    authors: Surowiec D,DePestel DD,Carver PL

    更新日期:2008-06-01 00:00:00

  • Benzalkonium Chloride: A Bronchoconstricting Preservative in Continuous Albuterol Nebulizer Solutions.

    abstract::For convenience, many pediatric hospitals are preparing solutions for continuous nebulized albuterol using the 0.5% 20-ml multidose albuterol dropper bottle. This product contains benzalkonium chloride (BAC) that, by itself, produces bronchospasm that is dose dependent and cumulative. The bronchoconstrictive effects o...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1002/phar.1929

    authors: Prabhakaran S,Abu-Hasan M,Hendeles L

    更新日期:2017-05-01 00:00:00

  • Clinical pharmacology of recombinant human erythropoietin (r-HuEPO).

    abstract::Recombinant human erythropoietin reverses the severe anemia associated with end-stage renal disease. Mean half-life values after a single intravenous bolus dose range from 4-13 hours. Renal clearance is not a significant route of elimination. Dosing schedules in chronic renal failure involve a single intravenous bolus...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:

    authors: Flaharty KK

    更新日期:1990-03-01 00:00:00

  • Argatroban therapy for antithrombin deficiency and mesenteric thrombosis: case report and review of the literature.

    abstract::Antithrombin deficiency is a hypercoagulable state that can increase the risk for thrombosis, especially in the presence of other procoagulant triggers. Unfractionated heparin and low-molecular-weight heparins may not provide effective anticoagulation since they require antithrombin for activity. Direct thrombin inhib...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1592/phco.24.6.659.34745

    authors: Dager WE,Gosselin RC,Owings JT

    更新日期:2004-05-01 00:00:00

  • Does the addition of pindolol accelerate or enhance the response to selective serotonin reuptake inhibitor antidepressants?

    abstract::Although in the last few years new antidepressants have become available in the United States, responses in many patients differ, from none, to partial, to delayed therapeutic response to the agents. If the antidepressant properties of these drugs could be enhanced or accelerated, it might be possible to improve patie...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1592/phco.19.3.205.30921

    authors: Puzantian T,Kawase K

    更新日期:1999-02-01 00:00:00

  • Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?

    abstract::The era of the integrase strand transfer inhibitors (INSTIs) for the treatment of human immunodeficiency virus (HIV) infection began with raltegravir in 2007. Since that time, several other INSTIs have been introduced including elvitegravir, dolutegravir, and, most recently, bictegravir, that have shown great utility ...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1002/phar.2246

    authors: Brooks KM,Sherman EM,Egelund EF,Brotherton A,Durham S,Badowski ME,Cluck DB

    更新日期:2019-05-01 00:00:00

  • Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin.

    abstract::Dabigatran, a direct thrombin inhibitor, is an oral anticoagulant indicated for the prevention of stroke in patients with atrial fibrillation (AF) and for the treatment and prevention of deep vein thrombosis and pulmonary embolism. Dabigatran, as well as the other new anticoagulants-rivaroxaban, apixaban, and edoxaban...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:10.1002/phar.1698

    authors: Wiggins BS,Northup A,Johnson D,Senfield J

    更新日期:2016-02-01 00:00:00

  • Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians.

    abstract::Nucleoside analogs (zidovudine, didanosine, zalcitabine, stavudine, abacavir, lamivudine) have been administered as antiretroviral agents for more than a decade. They undergo anabolic phosphorylation by intracellular kinases to form triphosphates, which inhibit human immunodeficiency virus replication by competitively...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1592/phco.21.1.11.34439

    authors: Stein DS,Moore KH

    更新日期:2001-01-01 00:00:00

  • Strategies in the management of acute myocardial infarction.

    abstract::Clinical trials continue to evaluate the pharmacologic management of myocardial infarction for benefits in mortality, degree of infarct artery patency, and frequency of reocclusion. The discovery of thrombus formation in the development of the myocardial infarction renewed interest in thrombolytic therapy. In appropri...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:

    authors: Talbert RL

    更新日期:1996-09-01 00:00:00

  • Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.

    abstract::Staphylococcus aureus (S. aureus) has proven to be a major pathogen with the emergence of methicillin-resistant S. aureus (MRSA) infections and recently with heteroresistant vancomycin-intermediate S. aureus (hVISA) and vancomycin-intermediate S. aureus (VISA) infections. Although vancomycin is traditionally a first-l...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1002/phar.1577

    authors: Gomes DM,Ward KE,LaPlante KL

    更新日期:2015-04-01 00:00:00

  • Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies.

    abstract:STUDY OBJECTIVE:To assess the pharmacokinetic profile of palifermin after intravenous dosing with either a collapsed dose of 180 microg/kg/day for 1 day or a standard dose of 60 microg/kg/day for 3 days, before and after myeloablative chemoradiotherapy and peripheral blood progenitor cell (PBPC) transplantation. DESIG...

    journal_title:Pharmacotherapy

    pub_type: 临床试验,杂志文章

    doi:10.1592/phco.27.10.1353

    authors: Zia-Amirhosseini P,Hurd DD,Salfi M,Cheah TC,Aycock J,Cesano A

    更新日期:2007-10-01 00:00:00

  • Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic.

    abstract:STUDY OBJECTIVES:To determine changes in bone mineral density (BMD) and T scores of patients after 2 years of teriparatide therapy, and to determine the number of fractures that occurred during therapy. DESIGN:Prospective, observational study. SETTING:Pharmacist-run teriparatide clinic in a private-practice endocrino...

    journal_title:Pharmacotherapy

    pub_type: 临床试验,杂志文章

    doi:10.1592/phco.27.6.779

    authors: Stroup JS,Rivers SM,Abu-Baker AM,Kane MP

    更新日期:2007-06-01 00:00:00

  • The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis.

    abstract:STUDY OBJECTIVE:To describe the pharmacokinetics and pharmacodynamics of fludarabine in patients with rheumatoid arthritis (RA). DESIGN:Open-label, staggered trial conducted in conjunction with a phase I-II clinical trial. SETTING:Government research hospital. PATIENTS:Twenty-six patients with refractory RA. INTERV...

    journal_title:Pharmacotherapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Knebel W,Davis JC Jr,Sanders WD,Fessler B,Yarboro C,Pucino F,Boumpas DT

    更新日期:1998-11-01 00:00:00

  • Absence of QTc-interval-prolonging or hemodynamic effects of a single dose of bitter-orange extract in healthy subjects.

    abstract:STUDY OBJECTIVE:To evaluate the hemodynamic and electrocardiographic effects of a single dose of commercially available bitter-orange dried-fruit extract, which is increasingly being used in dietary supplements. DESIGN:Randomized, double-blind, placebo-controlled, crossover study. SETTING:University of Connecticut, S...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1592/phco.2005.25.12.1719

    authors: Min B,Cios D,Kluger J,White CM

    更新日期:2005-12-01 00:00:00

  • Quinupristin-dalfopristin: an overview.

    abstract::Synercid (RP 59500), the first injectable streptogramin antibiotic, is composed of two semisynthetic pristinamycin derivatives, quinupristin and dalfopristin. Individually, each component has bacteriostatic activity against staphylococci and streptococci, but together, the agents exhibit synergy, leading to bactericid...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1592/phco.20.19.1469.34858

    authors: Delgado G Jr,Neuhauser MM,Bearden DT,Danziger LH

    更新日期:2000-12-01 00:00:00

  • Antimicrobial formulary management: a case study in a teaching hospital.

    abstract::The role of the formulary system for effective cost containment is becoming increasingly important. With antimicrobial agents taking up a large proportion of most pharmaceutical budgets, this group of agents is an obvious target for cost reduction. The responsible interchange of selected antimicrobial agents offers a ...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:

    authors: Wright DB

    更新日期:1991-01-01 00:00:00

  • Possible antiretroviral therapy-warfarin drug interaction.

    abstract::Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) has resulted in significant morbidity and mortality reductions. Lifelong antiretroviral therapy must be incorporated into each patient's medical regimen. Patients with HIV may also have simultaneous chronic medical conditions, resultin...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:10.1592/phco.28.7.945

    authors: Fulco PP,Zingone MM,Higginson RT

    更新日期:2008-07-01 00:00:00

  • Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast.

    abstract:STUDY OBJECTIVE:To determine the effect of a high-fat breakfast on single-dose, zidovudine (ZDV) pharmacokinetics. DESIGN:Open-label, randomized, crossover study. PATIENTS:Eighteen asymptomatic subjects (12 men, 6 women) infected with the human immunodeficiency virus (mean CD4 cell counts of 512 +/- 178/mm3). INTERV...

    journal_title:Pharmacotherapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Shelton MJ,Portmore A,Blum MR,Sadler BM,Reichman RC,Morse GD

    更新日期:1994-11-01 00:00:00

  • Pharmacotherapy of behavioral and psychological symptoms of dementia: time for a different paradigm?

    abstract::Behavioral and psychological symptoms of dementia can occur in 60-80% of patients with Alzheimer's disease or other dementing illnesses, and are important in that they are a source of significant caregiver stress and often precipitate nursing home placement. These symptoms, namely, aggression, delusions, hallucination...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1592/phco.21.1.74.34437

    authors: Rojas-Fernandez CH,Lanctot KL,Allen DD,MacKnight C

    更新日期:2001-01-01 00:00:00